Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protoporphyria, Erythropoietic | 9 | 2024 | 55 | 5.850 |
Why?
|
| Porphyrias | 2 | 2023 | 58 | 1.090 |
Why?
|
| Liver Diseases | 3 | 2023 | 1302 | 1.040 |
Why?
|
| Photosensitivity Disorders | 1 | 2023 | 80 | 0.860 |
Why?
|
| Dermatitis, Phototoxic | 1 | 2022 | 17 | 0.840 |
Why?
|
| Myoclonus | 1 | 2023 | 107 | 0.830 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2023 | 378 | 0.790 |
Why?
|
| Medicine, Ayurvedic | 1 | 2021 | 37 | 0.790 |
Why?
|
| Burkholderia pseudomallei | 1 | 2019 | 9 | 0.670 |
Why?
|
| Melioidosis | 1 | 2019 | 11 | 0.670 |
Why?
|
| Abdominal Pain | 2 | 2023 | 1063 | 0.670 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2019 | 42 | 0.660 |
Why?
|
| Lead Poisoning | 1 | 2021 | 321 | 0.650 |
Why?
|
| Flagellin | 1 | 2019 | 124 | 0.620 |
Why?
|
| Ferrochelatase | 3 | 2023 | 47 | 0.460 |
Why?
|
| Maleimides | 2 | 2010 | 113 | 0.440 |
Why?
|
| Aminophenols | 2 | 2010 | 86 | 0.430 |
Why?
|
| Heme | 3 | 2023 | 313 | 0.430 |
Why?
|
| Patients | 1 | 2019 | 906 | 0.410 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2010 | 410 | 0.390 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 4291 | 0.310 |
Why?
|
| Parents | 1 | 2019 | 3549 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 7475 | 0.240 |
Why?
|
| Communication | 1 | 2019 | 3849 | 0.240 |
Why?
|
| Porphobilinogen | 1 | 2023 | 9 | 0.230 |
Why?
|
| Porphyrias, Hepatic | 1 | 2023 | 6 | 0.230 |
Why?
|
| 5-Aminolevulinate Synthetase | 1 | 2023 | 64 | 0.220 |
Why?
|
| Protoporphyrins | 1 | 2023 | 165 | 0.210 |
Why?
|
| Dyskinesias | 1 | 2023 | 79 | 0.210 |
Why?
|
| Photophobia | 1 | 2023 | 71 | 0.200 |
Why?
|
| Neuroblastoma | 1 | 2010 | 1252 | 0.200 |
Why?
|
| Porphyria, Acute Intermittent | 1 | 2021 | 15 | 0.200 |
Why?
|
| Paresthesia | 1 | 2023 | 162 | 0.200 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2023 | 1903 | 0.190 |
Why?
|
| Chelation Therapy | 1 | 2021 | 77 | 0.190 |
Why?
|
| Erythema | 1 | 2023 | 262 | 0.190 |
Why?
|
| Anorexia | 1 | 2021 | 154 | 0.190 |
Why?
|
| Viral Tropism | 1 | 2021 | 102 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2024 | 8555 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 3726 | 0.170 |
Why?
|
| Tuberculosis | 2 | 2023 | 2001 | 0.170 |
Why?
|
| Pruritus | 1 | 2023 | 377 | 0.170 |
Why?
|
| Ultraviolet Rays | 1 | 2024 | 1078 | 0.160 |
Why?
|
| Macrophages, Alveolar | 1 | 2021 | 409 | 0.160 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 441 | 0.150 |
Why?
|
| Light | 1 | 2024 | 1344 | 0.150 |
Why?
|
| Codon, Nonsense | 1 | 2019 | 281 | 0.150 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2023 | 812 | 0.150 |
Why?
|
| Lead | 1 | 2021 | 880 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 1204 | 0.130 |
Why?
|
| Apoptosis | 2 | 2010 | 9501 | 0.130 |
Why?
|
| Humans | 20 | 2024 | 760621 | 0.120 |
Why?
|
| Malnutrition | 1 | 2021 | 640 | 0.120 |
Why?
|
| Iron | 1 | 2023 | 1786 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 783 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2021 | 1197 | 0.120 |
Why?
|
| Point Mutation | 1 | 2019 | 1594 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2019 | 1175 | 0.110 |
Why?
|
| Europe | 1 | 2020 | 3441 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 2622 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1447 | 0.100 |
Why?
|
| Anemia | 1 | 2021 | 1511 | 0.100 |
Why?
|
| Adult | 7 | 2024 | 219994 | 0.100 |
Why?
|
| Suicidal Ideation | 1 | 2021 | 1425 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2024 | 5961 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2010 | 115 | 0.090 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2010 | 60 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2019 | 2488 | 0.090 |
Why?
|
| Female | 9 | 2024 | 391270 | 0.090 |
Why?
|
| Colorimetry | 1 | 2010 | 153 | 0.090 |
Why?
|
| Weight Loss | 1 | 2021 | 2686 | 0.090 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2010 | 88 | 0.090 |
Why?
|
| Radiation-Protective Agents | 1 | 2010 | 88 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2024 | 54303 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4353 | 0.080 |
Why?
|
| Adolescent | 3 | 2023 | 87810 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 4550 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 4357 | 0.070 |
Why?
|
| Self Report | 1 | 2019 | 3711 | 0.070 |
Why?
|
| Mutation | 2 | 2022 | 29932 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2019 | 3047 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3224 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 12965 | 0.070 |
Why?
|
| Male | 7 | 2024 | 359744 | 0.070 |
Why?
|
| HIV Infections | 2 | 2021 | 17165 | 0.060 |
Why?
|
| Smoking | 1 | 2021 | 9073 | 0.060 |
Why?
|
| Porphobilinogen Synthase | 1 | 2023 | 27 | 0.060 |
Why?
|
| Cell Survival | 2 | 2010 | 5797 | 0.060 |
Why?
|
| Middle Aged | 4 | 2024 | 220352 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2010 | 2934 | 0.050 |
Why?
|
| Acyl Coenzyme A | 1 | 2022 | 57 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 25942 | 0.050 |
Why?
|
| Indoles | 1 | 2010 | 1829 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 20509 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 3442 | 0.050 |
Why?
|
| Chemokine CCL5 | 1 | 2021 | 215 | 0.050 |
Why?
|
| Intestines | 1 | 2010 | 1907 | 0.050 |
Why?
|
| Receptors, CXCR3 | 1 | 2021 | 238 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2021 | 316 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2021 | 488 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 748 | 0.040 |
Why?
|
| Tretinoin | 1 | 2022 | 519 | 0.040 |
Why?
|
| Chemotaxis | 1 | 2021 | 598 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 10827 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 657 | 0.040 |
Why?
|
| Macrophages | 2 | 2023 | 5745 | 0.040 |
Why?
|
| Aged | 2 | 2021 | 169152 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2019 | 41335 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 58741 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10446 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 8515 | 0.030 |
Why?
|
| Monocytes | 1 | 2023 | 2575 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 16939 | 0.030 |
Why?
|
| Cholesterol | 1 | 2022 | 2924 | 0.030 |
Why?
|
| Viral Load | 1 | 2021 | 3322 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2023 | 3392 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 40165 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 613 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 282 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 731 | 0.020 |
Why?
|
| Mice | 2 | 2010 | 81208 | 0.020 |
Why?
|
| Lung | 1 | 2023 | 9994 | 0.020 |
Why?
|
| beta Catenin | 1 | 2010 | 1043 | 0.010 |
Why?
|
| HIV-1 | 1 | 2021 | 6849 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22053 | 0.010 |
Why?
|
| Animals | 2 | 2010 | 167963 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15620 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 74359 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 23711 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 22023 | 0.010 |
Why?
|
Concepts
(130)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(35)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_